Clinical trials
Advanced Malignant Tumors clinical trials
Below are recruiting advanced malignant tumors clinical trials, each written for real people, not researchers. We’re tracking 1,019 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT07215988Recruiting
Studying insurance for skin cancer treatment
This study looks at how insurance covers immunotherapy given before surgery for certain skin cancers. It includes people with Merkel cell, mucosal melanoma, basal cell, or other rare skin cancers who are planning to have surgery.
Columbus, OhioAges 18 years+ - NCT07746141RecruitingPhase 1
Study of BG-85738 for advanced solid tumors with RAS mutations
This trial is testing a new drug called BG-85738, which may target cancer cells that have a specific change (mutation) in the RAS gene. The goal is to see if it is safe and works against advanced or spreading solid tumors.
South Brisbane, QueenslandAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT05159245RecruitingPhase 2
Targeted drug access for adults with advanced cancer
This trial helps match people with advanced, hard-to-treat cancers to targeted cancer drugs based on lab testing of their tumor. It may help if standard treatment isn’t working or isn’t available, and if your tumor has a “targetable” genetic change.
Turku, Southwest FinlandAges 18–100 - NCT05003895RecruitingPhase 1
CAR-T for solid tumors with high GPC3 protein
This early-phase trial tests a personalized CAR-T cell treatment for cancers that make a lot of a protein called GPC3. If you have advanced cancer that has already tried at least one standard treatment, and your tumor has enough GPC3, this study aims to see how well the treatment can shrink tumors and how safe it is.
Bethesda, MarylandAges 18–120 - NCT02838602Recruiting
Carbon beam radiation vs standard radiation for resistant tumors
This study compares carbon beam radiation with standard radiation for tumors that are less likely to respond to usual radiation. It aims to see whether carbon beams can improve control of the cancer while keeping side effects manageable.
AmiensAges 18 years+ - NCT06782425RecruitingPhase 1
Cell therapy for advanced stomach cancer with Claudin18.2 protein
This trial tests a new type of cell therapy (CAR-T) that targets a protein called Claudin18.2 found on some stomach, esophagus, and gastroesophageal junction cancers. The goal is to see if this treatment can shrink tumors or stop them from growing when other treatments have stopped working.
Anyang, HenanAges 18–75 - NCT07100210RecruitingPhase 1
Study of a new drug for advanced solid tumors that haven't responded to treatment
This trial tests a new drug, IL-22BP/LNP, for people with advanced solid tumors (like soft tissue sarcoma, head and neck cancer, melanoma) that have worsened after standard treatments. The main goals are to see if the drug is safe and tolerable, and to learn if it might help shrink or slow the cancer.
Chengdu, SichuanAges 18–70 - NCT05188859RecruitingPhase 2
Testing sintilimab, anlotinib, and chemo for pleural mesothelioma
This Phase 2 study tests whether adding three medicines—sintilimab, anlotinib, and standard platinum chemo—can control malignant pleural mesothelioma that cannot be removed by surgery. It may help shrink tumors and slow disease progression, but you must meet specific health and prior-treatment requirements.
Taiyuan, ShanxiAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07712029RecruitingPhase 2
A new drug combo for EGFR positive advanced solid tumors
This trial tests a new combination of two drugs—Becotatug Vedotin (a targeted therapy that delivers chemotherapy directly to EGFR-positive cancer cells) and Pucotenlimab (an immunotherapy that helps your immune system fight cancer). It is for people with advanced solid tumors that have not responded to standard treatments.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT04965077RecruitingPhase 1
First study of MIL97 for advanced solid tumors
This Phase 1 trial tests MIL97, a new treatment, in adults with advanced solid cancers that have come back or cannot be removed. The goal is to find a safe dose and see how the cancer responds.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07094113RecruitingPhase 1
AMG 410 alone or with other drugs for KRAS-altered advanced cancers
This study tests a new drug called AMG 410 by itself or with other medicines in people whose cancer has a specific change in the KRAS gene. It is for advanced or metastatic solid tumors that have not responded to standard treatments or who have chosen not to take them.
Duarte, CaliforniaAges 18 years+ - NCT06974812RecruitingPhase 1/Phase 2
Study of IBI3014 for advanced solid tumors
This trial tests a new drug called IBI3014 for people with advanced solid tumors that cannot be removed by surgery. It aims to see if the drug is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT06915753RecruitingPhase 1
TYRA-430 for advanced liver cancer and other tumors with specific genetic changes
This trial tests a new pill, TYRA-430, for people with advanced liver cancer (hepatocellular carcinoma) or other solid tumors that have certain genetic changes (in the FGF/FGFR pathways). It aims to see if the drug is safe and if it can shrink or slow the growth of the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07751042RecruitingPhase 1/Phase 2
Study of STX-003 with and without pembrolizumab for advanced solid tumors
This study tests an experimental drug called STX-1, given alone or with another drug that helps the immune system fight cancer. It is for people with advanced solid tumors, especially certain types of lung cancer or melanoma, who have already tried standard treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07734116RecruitingPhase 1/Phase 2
Nivolumab for solid tumors and epithelioid sarcoma
This trial tests a new immunotherapy drug (nivolumab) in children and adults with certain hard-to-treat solid tumors. It may help if standard treatments haven't worked or aren't an option.
Chiba, ChibaAges 12 years+ - NCT06096974RecruitingPhase 1
Study of YL-17231 for advanced solid tumors with RAS mutations
This trial tests a new drug called YL-17231 in people with advanced solid tumors that have specific changes (mutations) in the KRAS, HRAS, or NRAS genes. It is for patients whose cancer has stopped responding to or cannot tolerate standard treatments.
Cincinnati, OhioAges 18 years+ - NCT07161414RecruitingPhase 1
Study of rilvegostomig for advanced solid tumors
This study tests a new investigational drug, rilvegostomig, given as an injection under the skin. It is for people with advanced solid tumors that have not responded to or have progressed after standard treatments. The goal is to see how the drug behaves in the body and to assess its safety.
Huntersville, North CarolinaAges 18 years+ - NCT06249048RecruitingPhase 1/Phase 2
Study of STX-001 injection for advanced solid tumors
This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.
Scottsdale, ArizonaAges 18 years+ - NCT04997993RecruitingPhase 1
Leflunomide for PTEN-altered or HER2-negative metastatic cancers
This Phase 1 trial studies whether leflunomide can slow or control advanced (metastatic) cancers in people whose tumors have specific PTEN changes or who have HER2-negative breast cancer. It’s primarily a safety-and-dosing study, but it may offer benefit if your cancer matches the tumor marker requirements.
New York, New YorkAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT04114136RecruitingPhase 2
Study tests pembrolizumab or nivolumab plus a diabetes-like drug
This Phase 2 study tests whether adding a metabolic (diabetes-related) medicine to an immune therapy (pembrolizumab or nivolumab) can better control certain solid tumors. It may help people whose standard treatment would usually be pembrolizumab or nivolumab alone.
Pittsburgh, PennsylvaniaAges 18 years+
Hear when a new Advanced Malignant Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced malignant tumors?
- Yes. Clin2 currently lists 1,019 recruiting advanced malignant tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced malignant tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced malignant tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.